Alnylam Pharmaceuticals, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Q·Score Breakdown
8
Bullish
Overall
6.3
Neutral
Quality
Health
Growth
Valuation
Sentiment
ALNY
Consensus analyst target of $449.48 is 52% above current price.
UNH
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
BUY
Target $449.48 (+51.8%)
25 analysts
BUY
Target $387.27 (+5.0%)
26 analysts
Fundamentals
ALNY
UNH
74.6×
Trailing P/E
27.9×
21.2×
Forward P/E
17.8×
12.6%
Profit Margin
2.7%
80.8%
Gross Margin
18.8%
90.4%
ROE
12.2%
96.4%
Revenue Growth
2.0%
—
Earnings Growth
0.7%
0.38
Beta
0.41
—
Price / Book
—
$39.5B
Market Cap
$334.9B
$246 – $496
52-Week Range
$235 – $410
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →